Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics

Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.